Email Updates

Place quotation marks around exact phrases (e.g. "new york"). Note: Trial names have a space before the number (e.g. HVTN 100).

You are here

Home

Trial Search

Trial Name Prevention Option Phase Start Date Sponsors Countries Population Candidate(s) Status
HVTN 303 HIV Vaccine I HVTN Men Planned
Purpose 4/ HPTN 103 PrEP Open Label Injecting drug users Lenacapavir Planned
PURPOSE 3/ HPTN 102 PrEP Open Label Men Lenacapavir , TDF/FTC (Truvada) Planned
IAVI G003 HIV Vaccine I May 2022 South Africa, Rwanda Men, Women mRNA-1644 (eOD-GT8 60mer) Ongoing
IAVI G001 HIV Vaccine Open Label June 2018 Gates Foundation; NIAID; CHAVD United States of America Men, Women Completed
HPTN 074 PrEP, Treatment Open Label, III February 2015 HPTN, NIDA, NIAID Indonesia, Ukraine, Thailand HIV positive, Injecting drug users Completed
HPTN 091 PrEP Open Label March 2021 HPTN, Gilead United States of America, Brazil Men TAF/FTC (Descovy), TDF/FTC (Truvada)
HPTN 096 General, PrEP, Treatment Open Label, Other April 2022 HPTN; DIAID, NAID HIV positive, MSM Ongoing
HPTN 078 General, Treatment Other June 2016 NIAID (DAIDS ID: 11995) United States of America HIV positive, MSM Completed
HPTN 094/ INTEGRA General, PrEP, Treatment Demo Project, Open Label June 2021 NIAID (DAIDS ID: 38715) United States of America HIV positive, Injecting drug users, Men, Women Ongoing
HVTN 908 HIV Vaccine Open Label July 2009 NIAID (DAIDS ES 10806) United States of America Men JS7 DNA Vaccine, MVA/HIV62 vaccine Completed
HVTN 302 HIV Vaccine Open Label February 2022 NIAID (DAIDS-ES ID: 38791) United States of America Men, Women BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA Ongoing
HVTN 300 HIV Vaccine I May 2022 NIAID United States of America Men CH505TF Ongoing
IPCAVD 010/ HPX1002 HIV Vaccine I March 2016 Janssen Vaccines & Prevention B.V. Men, Women Ad26.Mos.HIV, gp140 Completed
PROMISE-EPI Combination Prevention Open Label December 2019 ANRS, Emerging Infectious Diseases Burkina Faso, Zambia Women Lamivudine Ongoing
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults Treatment I November 2018 Gilead Sciences United States of America Men Lenacapavir Completed
CALIBRATE Combination Prevention Open Label, II November 2019 Gilead Sciences United States of America, Dominican Republic, Puerto Rico Men, Women F/TAF, Lenacapavir , tenofovir, emtricitabine
PURPOSE 1 Combination Prevention III August 2021 Gilead Sciences South Africa Women F/TAF, Lenacapavir , F/TDF Ongoing
CAPELLA Combination Prevention III, II November 2019 Gilead Sciences United States of America, France, Italy, South Africa, Spain, Thailand, Canada, Dominican Republic, Germany, Japan, Taiwan HIV positive, Men, Women Lenacapavir Ongoing
PURPOSE 2 PrEP III June 2021 Gilead Sciences United States of America Men, MSM, Transgender men, Transgender women Lenacapavir , F/TDF Ongoing

Pages

CSVDoc